Abivax lists on Euronext Paris

Raises €57.7 million, market capitalisation €205 million

Paris – 26 June 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1], todaycelebrated the listing of Abivax, a biotech company specialising in the clinical development and commercialisation of anti-viral therapies. Abivax listed in Compartment B of Euronext Paris.

Abivax is a biotech company that aims to become a leader in the discovery, development and commercialisation of new anti-viral compounds. It focuses on some of the world’s most severe or life-threatening infectious diseases including chronic Hepatitis B, HIV/AIDS, Ebola, Dengue fever and Chikungunya. Abivax is based in France with operations in Paris, Évry and Montpellier, and does pioneering work with biotechnology institutes in Cuba , the CNRS in Montpellier, the Institute Pasteur and the Institute Curie in Paris as well as the Scipps Research Institute in Lo Jolla, California.

Abivax (ticker code: ABVX) was listed through the admission to trading of the 9,624,889 shares making up its equity, including 2,707,089 new shares issued under a Global Offering[2], after the full exercise of the extension option and over-allotment option.

The admission and issue price of Abivax shares was set at €21.30 per share. Market capitalisation was    205 million on the day of listing, and the transaction raised a total of  57.7 million.

Prof Hartmut Ehrlich, CEO of Abivax said:“We are proud to join the biotechnology companies listed on Euronext in Paris, with strong demand from institutional investors and, European family offices that showed their support very early on in our listing process, as well as retail investors.”

Dr Philippe Pouletty, founder and chairman of Abivax added:“Abivax will be able to pursue its leading strategy in immuno-virology with the development for commercialisation of its new anti-viral compounds, notably for patients suffering from chronic Hepatitis B, AIDS, Dengue fever and Chikungunya, building on the work of our research centre in Montpellier and our close ties with biotechnology institutions in Cuba and with France’s CNRS.”

Eric Forest, CEO of EnterNext, said: “We extend a warm welcome to Abivax as it lists on Euronext. Abivax is the ninth life sciences specialist to join our markets since the beginning of the year. In doing so, it becomes part of a community of over 70 listed biotech and medtech companies, the largest in Europe. Listing will enable Abivax to pursue its clinical development programme and prepare for the commercialisation of its new compounds. We are convinced that listing will serve the group’s growth strategy.”



[1]Small and medium-size companies
[2]
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

 

About Euronext
Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.9 trillion in market capitalisation as of end September 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. 
For the latest news, find us on Twitter  (www.twitter.com/euronext) and LinkedIn (www.linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2018, Euronext N.V. - All rights reserved.